Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-03-09 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
IMFINZI IMPROVED EFS IN RESECTABLE LUNG CANCER
Foreign Filer Report
2023-03-09 English
Imfinzi improved EFS in resectable lung cancer
Earnings Release Classification · 1% confidence The document begins with 'RNS Number : 3664S' and includes a date stamp '09 March 2023 07:00 GMT'. It details positive clinical trial results for a drug (Imfinzi) and concludes with contact information for RNS and the London Stock Exchange, explicitly stating: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure is characteristic of a general regulatory news service announcement, which fits the definition of Regulatory Filings (RNS) as a primary information provider announcement, rather than a specific financial report like 10-K or ER. Q1 2023
2023-03-09 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2023-03-08 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2023-03-08 English
Director/PDMR Shareholding
Remuneration Information Classification · 1% confidence The document is an official notification disseminated via RNS (RNS Number: 2133S) on March 8, 2023. The content explicitly details 'Transactions by Persons Discharging Managerial Responsibilities (PDMRs)' regarding the granting of share awards under company incentive plans (AZDBP and AZPSP) to executive directors like the CEO and CFO. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of 'Director's Dealing'.
2023-03-08 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is clearly identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), specifically the vesting of shares to the CEO, Pascal Soriot, under a bonus plan. This type of mandatory disclosure regarding insider transactions (Director's Dealing) is typically disseminated via regulatory news services. Since the document is a direct regulatory announcement provided by RNS, and it specifically details insider trading/share transactions by a director, the most appropriate classification is Director's Dealing (DIRS). Although RNS is the distribution channel, DIRS is the specific content type, which takes precedence over the general RNS fallback for specific events like insider trades.
2023-03-08 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.